FOREST BASKETT
CIK 1277631 · last filed 2026-03-12
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$23.97B
Companies
69
Total Filings
226
Lifetime Open-Market Net
-$842.47M
Filer Profile
Reported Address
2855 SAND HILL ROADMENLO PARK, CA 94025
Related Filers
SCOTT D SANDELL — 102 joint filings, latest 2025-03-14
PATRICK J KERINS — 73 joint filings, latest 2024-05-15
PETER J BARRIS — 50 joint filings, latest 2019-11-29
KRISHNA KITTU KOLLURI — 40 joint filings, latest 2016-09-20
Anthony A. Florence Jr. — 37 joint filings, latest 2025-03-12
NEA 12 GP, LLC — 36 joint filings, latest 2019-11-29
NEA Partners 12, Limited Partnership — 36 joint filings, latest 2019-11-29
Peter W. Sonsini — 35 joint filings, latest 2023-01-04
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KRRO | 10%+ Owner | 1,297,893 | $13.81 | $17.92M | $3.30M | 2 | 2026-03-12 |
| SGP | 10%+ Owner | 2,989,408 | $27.52 | $82.27M | $15.00M | 1 | 2026-02-11 |
| NeueHealth, Inc. (BHG) Delisted | Director | 488,702 | $16.35 | $7.99M | $34.99M | 5 | 2025-10-06 |
| BZFDW | 10%+ Owner | 3,674,745 | $0.01 | $30.9K | -$4.21M | 2 | 2025-03-14 |
| NeueHealth, Inc. (NEUE) Delisted | 10%+ Owner | — | $6.75 | — | $0 | 2 | 2024-10-03 |
| MBX | 10%+ Owner | 3,614,486 | $59.02 | $213.33M | $8.00M | 1 | 2024-09-17 |
| SGMT | 10%+ Owner | 3,000,275 | $10.88 | $32.64M | $0 | 1 | 2024-01-31 |
| SVRA | 10%+ Owner | 24,471,264 | $5.30 | $129.70M | $1000.0K | 1 | 2023-07-19 |
| MIRM | 10%+ Owner | 1,548 | $98.22 | $152.0K | $6.75M | 2 | 2023-06-15 |
| COUR | 10%+ Owner | 10,661,886 | $5.22 | $55.66M | $0 | 4 | 2023-02-17 |
| MINERVA SURGICAL INC (UTRS) Delisted | 10%+ Owner | 1,721,853 | $0.00 | $172 | $30.00M | 1 | 2023-02-10 |
| Arcellx, Inc. (ACLX) Delisted | 10%+ Owner | 0 | $115.07 | $0 | -$51.2K | 1 | 2022-12-22 |
| Akouos, Inc. (AKUS) Delisted | 10%+ Owner | 0 | $13.29 | $0 | $10.00M | 2 | 2022-12-02 |
| IONQ.WS | 10%+ Owner | 175,378 | $25.41 | $4.46M | $0 | 1 | 2022-11-18 |
| AVEO PHARMACEUTICALS, INC. (AVEO) Delisted | 10%+ Owner | 3,952,957 | $15.00 | $59.29M | $24.62M | 17 | 2022-10-21 |
| GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | 10%+ Owner | 0 | $0.00 | $0 | $21.03M | 4 | 2022-05-26 |
| HOOD | Director | 36,688 | $112.57 | $4.13M | -$29.6K | 5 | 2022-05-04 |
| TRVI | 10%+ Owner | 10,421,428 | $15.90 | $165.70M | $30.00M | 4 | 2022-04-13 |
| Enliven Therapeutics, Inc. (IMRA) Delisted | 10%+ Owner | 872,668 | $14.59 | $12.73M | $54.98M | 3 | 2022-01-11 |
| Metacrine, Inc. (MTCR) Delisted | 10%+ Owner | 3,022,957 | $0.49 | $1.50M | $9.51M | 2 | 2021-12-27 |
| ARDX | 10%+ Owner | 6,207,480 | $3.58 | $22.22M | $80.59M | 10 | 2021-12-27 |
| GLUE | 10%+ Owner | 5,973,296 | $14.07 | $84.04M | $19.95M | 1 | 2021-06-30 |
| Desktop Metal, Inc. (DM) Delisted | 10%+ Owner | 81 | $4.96 | $402 | $0 | 1 | 2021-06-10 |
| Eargo, Inc. (EAR) Delisted | 10%+ Owner | 81 | $2.57 | $208 | $5.60M | 2 | 2021-05-26 |
| MRKR | 10%+ Owner | 1,071,428 | $1.15 | $1.23M | $10.00M | 1 | 2021-03-18 |
| Regulus Therapeutics Inc. (RGLS) Delisted | 10%+ Owner | 645,106 | $8.16 | $5.26M | $3.96M | 3 | 2020-12-07 |
| SPT | 10%+ Owner | 6,065,024 | $10.80 | $65.50M | -$567.90M | 3 | 2020-11-17 |
| NET | 10%+ Owner | 224,970 | $306.53 | $68.96M | -$76.53M | 6 | 2020-11-13 |
| Mersana Therapeutics, Inc. (MRSN) Delisted | 10%+ Owner | 0 | $29.08 | $0 | $14.79M | 4 | 2020-09-16 |
| Inozyme Pharma, Inc. (INZY) Delisted | 10%+ Owner | 2,000,533 | $4.00 | $8.00M | $4.00M | 1 | 2020-07-28 |
| NKTX | 10%+ Owner | 2,902,115 | $2.91 | $8.45M | $12.00M | 1 | 2020-07-16 |
| Adaptimmune Therapeutics PLC (ADAP) Delisted | 10%+ Owner | 82,978,668 | $0.06 | $4.80M | $5.00M | 1 | 2020-01-28 |
| NITE | 10%+ Owner | 0 | $39.65 | $0 | $0 | 1 | 2019-06-07 |
| TESARO, Inc. (TSRO) Delisted | 10%+ Owner | 0 | — | — | $73.04M | 7 | 2019-01-22 |
| ESTC | 10%+ Owner | 655,522 | $83.39 | $54.66M | $0 | 1 | 2018-10-10 |
| ASND | 10%+ Owner | 82,978,668 | $263.51 | $21.87B | $49.02M | 4 | 2018-09-10 |
| Surface Oncology, Inc. (SURF) Delisted | 10%+ Owner | 3,179,544 | $1.07 | $3.40M | $2.00M | 1 | 2018-04-23 |
| Tintri, Inc. (TNTR) Delisted | 10%+ Owner | — | — | — | $0 | 1 | 2018-03-02 |
| Oruka Therapeutics, Inc. (ABIO) Delisted | 10%+ Owner | 0 | $28.80 | $0 | -$731.3K | 1 | 2018-02-27 |
| Cascadian Therapeutics, Inc. (CASC) Delisted | 10%+ Owner | 10,882,574 | — | — | $0 | 1 | 2018-02-22 |
| APPN | 10%+ Owner | 27,242 | $34.76 | $946.9K | -$66.07M | 4 | 2018-02-15 |
| SYNLOGIC, INC. (SYBX) Delisted | 10%+ Owner | 281,929 | $0.69 | $194.5K | $0 | 2 | 2018-01-26 |
| Care.com Inc (CRCM) Delisted | 10%+ Owner | 433 | — | — | $0 | 2 | 2017-11-08 |
| RYTM | 10%+ Owner | 4,909,956 | $104.71 | $514.12M | $9.35M | 1 | 2017-10-10 |
| MULESOFT, INC (MULE) Delisted | 10%+ Owner | 12,679,970 | — | — | $0 | 1 | 2017-03-22 |
| Achaogen, Inc. (AKAO) Delisted | 10%+ Owner | 5,215,128 | — | — | $6.75M | 1 | 2016-12-19 |
| Tableau Software Inc (DATA) Delisted | Director | 10,833 | — | — | -$606.92M | 18 | 2016-12-06 |
| Ra Pharmaceuticals, Inc. (RARX) Delisted | 10%+ Owner | 1,858,450 | — | — | $4.39M | 1 | 2016-10-31 |
| Roka BioScience, Inc. (ROKA) Delisted | 10%+ Owner | 321,681 | — | — | $4.60M | 3 | 2016-09-30 |
| Epizyme, Inc. (EPZM) Delisted | 10%+ Owner | 5,854,351 | $1.47 | $8.61M | $23.85M | 4 | 2016-01-12 |
| SUPN | 10%+ Owner | 71,749 | $41.64 | $2.99M | -$3.71M | 3 | 2015-11-12 |
| Avalo Therapeutics, Inc. (CERC.U) Delisted | 10%+ Owner | 594,245 | — | — | $0 | 1 | 2015-10-20 |
| SYNLOGIC, INC. (MIRN) Delisted | 10%+ Owner | 2,114,375 | — | — | $6.00M | 1 | 2015-10-06 |
| BOX | 10%+ Owner | 2,091,457 | $33.75 | $70.59M | $0 | 1 | 2015-01-29 |
| CVENT INC (CVT) Delisted | 10%+ Owner | 10,000 | $8.52 | $85.2K | -$46.32M | 5 | 2014-11-28 |
| DERM | 10%+ Owner | 3,502,922 | $7.23 | $25.33M | $1.11M | 1 | 2014-10-08 |
| Viracta Therapeutics, Inc. (SNSS) Delisted | 10%+ Owner | 1,376,495 | $18.62 | $25.63M | -$283.8K | 4 | 2014-08-29 |
| Loxo Oncology, Inc. (LOXO) Delisted | 10%+ Owner | 1,789,420 | — | — | $3.00M | 1 | 2014-08-06 |
| AUDIENCE INC (ADNC) Delisted | Director | 0 | — | — | -$1.08M | 8 | 2013-12-04 |
| FUSION-IO, INC. (FIO) Delisted | Director | 7,053,379 | — | — | -$44.16M | 19 | 2013-11-21 |
| XOOM Corp (XOOM) Delisted | 10%+ Owner | 0 | — | — | $0 | 1 | 2013-10-31 |
| GRPN | 10%+ Owner | 2,709,248 | $18.73 | $50.74M | -$331.4K | 2 | 2013-09-17 |
| Clovis Oncology, Inc. (CLVS) Delisted | 10%+ Owner | 494 | $0.08 | $40 | $17.11M | 2 | 2013-06-05 |
| WDAY | 10%+ Owner | 2,321,212 | $185.70 | $431.05M | $0 | 2 | 2013-04-11 |
| Millennial Media Inc. (MM) Delisted | 10%+ Owner | 8,196,614 | — | — | -$21.48M | 2 | 2012-10-30 |
| HYPERION THERAPEUTICS INC (HPTX) Delisted | 10%+ Owner | 1,639,218 | — | — | $5.00M | 1 | 2012-08-02 |
| INNERWORKINGS INC (INWK) Delisted | 10%+ Owner | 15,000 | — | — | -$12.62M | 7 | 2012-03-30 |
| ECHO | 10%+ Owner | 4,000 | $93.14 | $372.6K | $0 | 1 | 2012-03-01 |
| ARYx Therapeutics, Inc. (ARYX) Delisted | 10%+ Owner | 0 | — | — | -$326.3K | 1 | 2011-03-14 |
Recent Filings · Page 6 of 23
226 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-08-13 | NET | Sell (S) | −738,278 | -$28.39M | EDGAR |
| 2020-08-10 | NET | Mixed | +289,998 | -$3.45M | EDGAR |
| 2020-07-28 | Inozyme Pharma, Inc. (INZY) Delisted | Mixed | +2,437,689 | $4.00M | EDGAR |
| 2020-07-28 | GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | Buy (P) | +3,151,260 | $7.09M | EDGAR |
| 2020-07-16 | NKTX | Mixed | +2,902,115 | $12.00M | EDGAR |
| 2020-07-01 | Akouos, Inc. (AKUS) Delisted | Mixed | +4,294,207 | $10.00M | EDGAR |
| 2020-06-22 | AVEO PHARMACEUTICALS, INC. (AVEO) Delisted | Buy (P) | +1,428,571 | $7.50M | EDGAR |
| 2020-06-17 | ARDX | Sell (S) | −43 | -$274 | EDGAR |
| 2020-06-12 | ARDX | Mixed | −2,499,957 | -$719.0K | EDGAR |
| 2020-05-21 | NET | Mixed | +69,983 | -$9.64M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.